Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Essential iris atrophy is a clinical variant of iridocorneal endothelial (ICE) syndrome, characterized by progressive iris atrophy and holes present on the surface of the iris, corneal edema, corectopia, uveal ectropion and anterior synechiae. Secondary glaucoma is also a common complication of the disease.
No clinical trials have been registered for essential iris atrophy.
5 publications have been identified in PubMed for essential iris atrophy. Research spans Review / Meta-Analysis (50%) and Case Report / Case Series (50%).
Fidan DG (2026). [PMID: 41489923](https://pubmed.ncbi.nlm.nih.gov/41489923/). *Ocul Immunol Inflamm*. [Case Report / Case Series]
Borodi PG (2026). [PMID: 42146950](https://pubmed.ncbi.nlm.nih.gov/42146950/). *Rom J Ophthalmol*. [Case Report / Case Series]
Tripathi M (2025). [PMID: 40586185](https://pubmed.ncbi.nlm.nih.gov/40586185/). *Indian J Ophthalmol*. [Review / Meta-Analysis]
Ma H (2025). [PMID: 41127405](https://pubmed.ncbi.nlm.nih.gov/41127405/). *Front Ophthalmol (Lausanne)*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 6:09 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center